Uvajanje preiskave PET/CT na Onkološkem inštitutu

PET/CT using 18F-fluorodeoxyglucose (FDG-PET/CT) is performed at the Institute of Oncology Ljubljana. PET/CT combines Positron Emission Tomography, which shows metabolism and function of the cells, with Computed Tomography, which shows detailed anatomy. FDG –PET/CT plays a major part in diagnostic evaluation of patients with suspected malignant tumors, in staging of malignancies and in therapy monitoring. Correct preparation of patients for the PET is important to ensure maximum diagnostic yield. The most important steps to be taken are control of glucose level, minimizing effects of physiological activity, and timing of scan performance. Due to a number of causes yielding false negative or false positive results, several interpretation criteria should be used to evaluate images.Ni abstrakta

Launching FDG PET-CT Imaging at the Institute of Oncology Ljubljana

PET/CT using 18F-fluorodeoxyglucose (FDG-PET/CT) is performed at the Institute of Oncology Ljubljana. PET/CT combines Positron Emission Tomography, which shows metabolism and function of the cells, with Computed Tomography, which shows detailed anatomy. FDG –PET/CT plays a major part in diagnostic evaluation of patients with suspected malignant tumors, in staging of malignancies and in therapy monitoring. Correct preparation of patients for the PET is important to ensure maximum diagnostic yield. The most important steps to be taken are control of glucose level, minimizing effects of physiological activity, and timing of scan performance. Due to a number of causes yielding false negative or false positive results, several interpretation criteria should be used to evaluate images

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma

Our aim was to test the efficacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) in patients with differentiated thyroid carcinoma (DTC) in whom endogenous TSH stimulation was not an option due to the poor patient's physical condition or due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients, who already have undergone total or near-total thyroidectomy and radioiodine ablation and 0–12 (median 5) RITs after L-thyroxin withdrawal. Our patients received altogether 44 RITs using rhTSH while on L-thyroxin. Six to 12 months after the first rhTSH-aided RIT, PR and SD was achieved in 3/18 (17%) and 4/18 patients (22%), respectively. In most patients (n = 12; 61%) disease progressed despite rhTSH-aided RITs. As a conclusion, rhTSH-aided RIT proved to add some therapeutic benefit in 39% our patients with metastatic DTC, who otherwise could not be efficiently treated with RIT

Povzetek smernic diagnostike in zdravljenja diferenciranega raka ščitnice

no abstractni abstrakt

Summary guidelines of diagnosis and treatment of differented thyroid cancer

Med vsemi bolniki z raki, ki jih zdravimo, ima raka ščitnice le 1 %. Leta 2013 je bilo po podatkih Registra raka v Sloveniji zdravljenih 160 bolnikov z rakom ščitnice. Porast števila bolnikov z rakom ščitnice v zadnjem desetletju je skoraj v celoti zaradi papilarnega raka ščitnice, še posebno papilarnega mikrokarcinoma, ki ima odlično prognozo. Velika večina bolnikov z rakom ščitnice je povsem ozdravljena. Zaradi dobre prognoze bolnikov z rakom ščitnice je v zadnjem desetletju prišlo do bistvenih sprememb v obravnavi bolnikov z rakom ščitnice. Strokovnjaki z Onkološkega inštituta, Klinike za nuklearno medicino UKC Ljubljana in Inštituta za patologijo Medicinske fakultete v Ljubljani smo pripravili Smernice diagnostike in zdravljenja raka ščitnice, v katerih so opisani sodobni postopki diagnosticiranja in zdravljenja raka ščitnice.Cancer of the thyroid gland comprises only 1% among all patients with cancer that are treated. In 2013, according to the Cancer Registry of Slovenia, 160 patients with thyroid cancer were treated in Slovenia. The increase in the number of patients with thyroid cancer in the last decade is almost entirely due to papillary thyroid cancer, especially papillary microcarcinoma, which has an excellent prognosis. The vast majority of patients with thyroid cancer are completely cured. Due to the good prognosis for patients with thyroid cancer in the last decade, there have been significant changes in the management of patients with thyroid cancer. Experts from the Institute of Oncology, Department of Nuclear Medicine of UKC Ljubljana, and the Institute of Pathology, Faculty of Medicine Ljubljana, prepared Guidelines for diagnosis and treatment of thyroid cancer that describe the modern methods of diagnosis and treatment of thyroid cancer